<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270840</url>
  </required_header>
  <id_info>
    <org_study_id>Budapest Upgrade CRT 009-4.1</org_study_id>
    <nct_id>NCT02270840</nct_id>
  </id_info>
  <brief_title>Budapest Upgrade CRT Study (Version 009-4.1)</brief_title>
  <official_title>Effect of Biventricular Upgrade on Left Ventricular Reverse Remodeling and Clinical Outcomes in Patient With Left Ventricular Dysfunction and Intermittent or Permanent Apical/Septal Right Ventricular Pacing (Budapest CRT Upgrade Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University Heart and Vascular Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmahungary Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Semmelweis University Heart and Vascular Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of biventricular upgrade on left ventricular reverse remodeling and clinical outcomes&#xD;
      in patient in left ventricular dysfunction and intermittent or permanent apical/septal right&#xD;
      ventricular pacing (Budapest CRT upgrade study)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to investigate the effect of upgrade to a CRT-D device on clinical&#xD;
      and echocardiographic response at 12-month in patients with left ventricular dysfunction&#xD;
      (LVEF ≤35%), symptomatic heart failure (NYHA II, III, IV-a), and intermittent or permanent&#xD;
      right ventricular pacing with paced QRS complex ≥ 150 ms compared to continued therapy with a&#xD;
      single or dual chamber pacemaker (PM) or ICD.&#xD;
&#xD;
      Prospective, post-market, international multicenter randomized controlled trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>A composite clinical and echocardiographic end point comprising the first occurrence of a non-fatal heart failure event, all-cause mortality, or &lt; 15% reduction in echocardiography determined LVESV from baseline to 12-month.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>CRT-D</arm_group_label>
    <description>Patients currently implanted with a single or dual chamber pacemaker or ICD will be upgraded to CRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Only ICD</arm_group_label>
    <description>In the ICD arm, choosing single or dual chamber device is based upon the investigator's discretion.&#xD;
Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-D</intervention_name>
    <description>Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).</description>
    <arm_group_label>CRT-D</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Altogether 360 subjects will be enrolled at the European and Israeli study sites,&#xD;
        randomized in the rate of 3:2 (CRT-D:ICD groups).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients over the age of 18 (expected survival time: over 1 year)&#xD;
&#xD;
          -  Patients with ischemic or non-ischemic cardiomyopathy;&#xD;
&#xD;
          -  Those implanted with a single or dual chamber ICD or implanted with a single or dual&#xD;
             chamber pacemaker at least 6 months before inclusion;&#xD;
&#xD;
          -  Elective generator replacement or upgrade from pacemaker-only to ICD therapy may be&#xD;
             indicated at the time of enrollment, but are not required;&#xD;
&#xD;
          -  Right ventricular pacing 20-100% in at least the last 90 days before enrollment (with&#xD;
             an optimal AV interval based on the physician's discretion to avoid unnecessary right&#xD;
             ventricular stimulation);&#xD;
&#xD;
          -  Symptomatic heart failure for at least 3 months before inclusion;&#xD;
&#xD;
          -  NYHA functional class II or III, or IV a;&#xD;
&#xD;
          -  Left ventricular ejection fraction measured by echocardiography ≤ 35%;&#xD;
&#xD;
          -  Paced QRS complex ≥ 150 ms;&#xD;
&#xD;
          -  Optimal heart failure medical therapy;&#xD;
&#xD;
          -  Informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intrinsic QRS with LBBB morphology (measured at VVI 40 bpm setting as per protocol);&#xD;
&#xD;
          -  CABG or PCI in the past 3 months;&#xD;
&#xD;
          -  Acute myocardial infarction in the past 3 months;&#xD;
&#xD;
          -  Unstable angina;&#xD;
&#xD;
          -  Planned coronary revascularization (PCI or CABG);&#xD;
&#xD;
          -  Planned cardiac transplantation;&#xD;
&#xD;
          -  Acute myocarditis;&#xD;
&#xD;
          -  Infiltrative myocardial disease;&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy;&#xD;
&#xD;
          -  Severe primary mitral and aortic valve stenosis or regurgitation;&#xD;
&#xD;
          -  Women who are pregnant or plan to become pregnant or breastfeeding;&#xD;
&#xD;
          -  Subjects who are unable or unwilling to cooperate with the study protocol;&#xD;
&#xD;
          -  Tricuspid valve prosthesis;&#xD;
&#xD;
          -  Any serious disease likely to interfere with the conduct of the study;&#xD;
&#xD;
          -  Participation in other clinical trial;&#xD;
&#xD;
          -  Patients geographically not stable or unavailable for follow-up;&#xD;
&#xD;
          -  Chronic, severe renal dysfunction (creatinine value &gt; 200 μmol/l);&#xD;
&#xD;
          -  Severe RV dilatation (RV basal diameter &gt;50mm);&#xD;
&#xD;
          -  Severe tricuspid insufficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentina Kutyifa, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Rochester Medical Center, Rochester, NY, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilan Goldenberg, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>Sheba Medical Center Tel-Hashomer, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Béla Merkely, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semmelweis University Hearth and Vascular Center, Budapest, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annamaria Kosztin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Semmelweis University Hearth and Vascular Center, Budapest, Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IK+EM Clinic of Cardiology</name>
      <address>
        <city>Praha</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Clinic St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Department of Internal Medicine and Cardiology Center, Faculty of Medicine, University of Szeged</name>
      <address>
        <city>Szeged</city>
        <state>Csongrád</state>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Depratment of Cardiology, Military Hospital, Hungarian Army Medical Center</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pécs Medical School, Heart Institute</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of Silesia, Department of Electrocardiology</name>
      <address>
        <city>Katowice</city>
        <zip>40-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Górnośląski Ośrodek Kardiologii</name>
      <address>
        <city>Katowice</city>
        <zip>40-629</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Interventional Cardiology, Medical University of Lodz,</name>
      <address>
        <city>Lodz</city>
        <zip>90-549</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC-Tronik</name>
      <address>
        <city>Lodz</city>
        <zip>90-553</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Stefan Wyszynski Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coronary Artery Disease II. Dept. Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bieganski Specialty Regional Hospital, Dept. of Cardiology</name>
      <address>
        <city>Łódź</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Blood Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>SI-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovenia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac resynchronization therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

